Call Extraction: CDL Nuclear — Strategy Center Discussion

DDX ID: 0363 Date: 2025-08-27 Duration: ~56 minutes (but only ~12 minutes of actual conversation; rest is MDCN coaching framework and SPICED analysis) Participants: Phil Cranmer — CDL Nuclear. Daniel Wheaton, Skylar Talley — MedScout. Call type: Demo rescheduling call that became an impromptu discovery conversation about CDL’s market positioning and clinical champion challenge. Triage: Rich despite brevity. Phil’s comments about market evolution, the CTA complementarity positioning, and the “mind share” challenge are high-value fingerprint material. 4 distinct insights.

Distinct Insights

What: Phil: “The one thing we struggle with is it’s we know the patients are there. We know patients will benefit from this, right? It’s almost gaining mind share within cardiology.” He elaborated that the challenge isn’t identifying demand but creating advocates within practices who will champion PET adoption against inertia and competing modalities.

So what: CDL has a demand problem that isn’t about demand. The patients exist. The clinical evidence exists. The ASNC endorsement exists. But cardiac PET adoption requires a specific physician inside the practice to become the internal champion who pushes for the investment. Without that champion, even willing hospital administrators have no one to operationalize the decision. This means CDL’s sales cycle has two phases: (1) identify the right facility (claims data handles this), and (2) develop a clinical champion within that facility (relationship-building, education, trust). Phase 2 is where CDL struggles, and it’s the phase that claims data alone can’t solve. The implication for CDL’s commercial model: their sales reps aren’t just selling equipment — they’re investing time educating cardiologists to become PET advocates. This education burden directly extends sales cycles and limits how many opportunities each rep can work simultaneously.

Speaker credibility: Phil Cranmer, national operations. Very high — he’s identifying the core company-wide challenge, not a territory-specific issue. Scope: Company-wide sales challenge. Motion: Both (mind share applies to hospital and private practice, though hospital multi-stakeholder dynamics likely amplify it).

2. CDL positions CTA and cardiac PET as complementary, not competitive — and uses risk stratification as the delineator

What: Phil: “It’s not an either or modality, right? Like our sales team will go into the hospital and be like, no, we don’t need PET. Where are you doing CTA? Yeah. Well, you know what? It’s not an either or it’s both.” He described the clinical delineation: CTA for low-to-intermediate risk patients, cardiac PET for moderate-to-high risk patients, and specific clinical scenarios where PET is the only appropriate choice (post-catheterization, known disease history, multivessel disease). Phil also shared that CDL has developed educational materials — an infographic-turned-white-paper — that maps this complementary positioning.

So what: CDL’s competitive response to CTA (coronary CT angiography) isn’t “PET is better than CTA.” It’s “both are necessary, and here’s which patients go where.” This is a sophisticated positioning strategy because it neutralizes the most common objection CDL encounters — “we already do CTA, we don’t need PET.” By agreeing that CTA is great for its patient population, CDL’s reps validate the cardiologist’s current practice rather than challenging it, then expand the conversation to the patients CTA doesn’t serve well. The risk stratification framework (low risk = CTA, high risk = PET) gives cardiologists a clinical decision rule rather than asking them to choose between technologies. This has a data implication: facilities already doing CTA aren’t competitors to avoid — they’re targets with existing cardiac imaging sophistication who are more likely to understand the value of adding PET for their higher-risk patients. CTA presence signals progressiveness and referral infrastructure, not competitive displacement risk.

Speaker credibility: Phil, describing CDL’s actual sales positioning and showing their educational materials. Very high. Scope: Company-wide sales positioning strategy. Motion: Both, but likely more relevant for hospital motion where CTA is more common.

3. The cardiac PET market shifted from “if” to “when” over the last three years

What: Phil: “I think I shared this with you three years ago. They were debating whether you would or you wouldn’t. Now, it’s not a matter of if it’s really a matter of, yeah, I got to do it. It’s just a matter of how and when, yeah, right? In most cases, in most cases.”

So what: Phil is describing a market maturation inflection. Three years ago (roughly 2022), CDL had to convince facilities that cardiac PET was worth considering at all — a “should we even do this?” conversation. Now, most facilities CDL engages already accept that cardiac PET is necessary — the conversation is about implementation logistics, timing, and which vendor to use. This shift has significant implications for CDL’s go-to-market: (1) the education burden, while still real, has moved from “why PET?” to “how and when PET?” — a shorter education cycle per opportunity; (2) the competitive landscape is intensifying because more vendors are entering a market that’s now accepted rather than speculative; (3) CDL’s first-mover advantage in turnkey cardiac PET solutions becomes more valuable as demand accelerates. Phil’s qualifier — “in most cases” — suggests there are still holdout markets or practice types where adoption isn’t yet accepted, but the overall trend is toward inevitability.

Speaker credibility: Phil, with three years of firsthand observation. Very high. Scope: Market-wide, not CDL-specific. Motion: Both.

4. CTA usage and AI platform adoption (HeartFlow) as targeting intelligence signals

What: Phil: “What does it mean if they’re doing CTA, if they’re billing CTA, and even using someone like HeartFlow or clearly some AI platform? Like… again, it’s just understanding that procedural behavior like what headwinds could we encounter? Well, if they’re already doing CTA great. So, I got to go in there locked and loaded ready to defend PET and understand what they’re doing for their moderate to high risk patients, right?” Regarding AI platforms specifically, Phil said they neither help nor hurt: “It just gives us more information is all.”

So what: Phil is asking for claims data to function not just as a volume filter (who does SPECT) but as a behavioral intelligence layer (what else they do). A facility billing CTA tells CDL’s rep to prepare the complementary positioning defense (Insight #2). A facility using HeartFlow (AI-powered CTA analysis) tells the rep this practice is tech-forward and invested in CTA sophistication — they’ll need a stronger argument for why PET adds value on top of their existing AI-enhanced CTA workflow. Phil doesn’t see CTA or AI-CTA as threats; he sees them as intelligence that determines which sales playbook to run. This is a more nuanced use of claims data than simple “has SPECT, no PET” filtering — it’s about understanding the prospect’s full procedural posture to customize the approach. The hospital division would benefit most from this dynamic targeting since hospitals are more likely to have CTA and AI platforms than private practices.

Speaker credibility: Phil, articulating a specific targeting need. High. Scope: Primarily hospital motion (CTA and AI platforms more common in hospital settings). Motion: Hospital primarily, some private practice relevance.

Transcription Notes

“Cath” in the transcript refers to cardiac catheterization — correctly noted in the MDCN’s technical clarification.
HeartFlow correctly identified as an AI-powered CTA analysis platform. Not a transcription error.
“Skylar Talley” listed as participant but does not appear to speak in the transcript content — may have been silent or joined briefly. Skylar referenced elsewhere as a MedScout team member.
“S Fathom Notetaker” in party names — this is an automated meeting recorder, not a person.
“mpi” — myocardial perfusion imaging, a type of nuclear cardiac study. Phil uses this interchangeably with SPECT in context. Not a transcription error but worth noting: MPI is the clinical indication, SPECT is the imaging technique. CDL uses both terms.
The MDCN for this call includes extensive coaching notes and SPICED analysis that were added by the MedScout team post-call, not part of the original conversation. The actual transcript content is relatively brief (~12 minutes of Phil talking).

Term Bank Addition Candidates

HeartFlow = AI-powered CTA analysis platform. Mentioned by Phil as an indicator of practice sophistication.
MPI (myocardial perfusion imaging) = clinical study type that SPECT performs. Phil uses “mpi” alongside “SPECT” — they’re related but not identical terms.